Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.
Adding a targeted leukemia drug to intensive chemotherapy may improve outcomes for patients with relapsed acute myeloid leukemia who face limited choices.
The FLAG-QUIDA trial assessed quizartinib—a second-generation FLT3 inhibitor—combined with intensive FLAG-IDA salvage chemotherapy in R/R AML patients, a notoriously treatment-refractory population. The PETHEMA consortium multicenter design across Spain provides a solid evidence base for this combination approach, which could improve bridge-to-transplant rates in FLT3-mutated AML.
What the study was
- Study design
- Phase I-II multicenter clinical trial
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Am J Hematol
Why it surfaced
Phase I-II data for a clinically approved FLT3 inhibitor in a novel combination salvage regimen; PETHEMA multicenter; published in American Journal of Hematology; addresses extreme unmet need in R/R AML.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.